Loading...
Market
How many CAR-T therapies will FDA approve in 2025 including Aucatzyl?
2
Resolution / Starting Odds
1-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
FDA announcements and press releases
Story
FDA Approves Autolus Therapeutics' Aucatzyl for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Under FELIX Program
Nov 8, 2024, 09:24 PM
The U.S. Food and Drug Administration (FDA) has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel – obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This approval, part of the FELIX program, marks a significant milestone for the company and provides a new treatment option for patients suffering from this aggressive form of leukemia. Despite earlier rumors and a temporary dip in share prices, the official announcement has confirmed the FDA's decision, which is expected to positively impact Autolus Therapeutics' market position.
View original story
Similar markets
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%